Pocket-Sized heart test could catch hidden AFib before it strikes
NCT ID NCT07468123
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an artificial intelligence program can use a simple, single-lead handheld ECG device to find people with undiagnosed atrial fibrillation (AF), a common heart rhythm problem. About 200 adults aged 50-90 will use a device at home and complete surveys. The goal is to see if this approach is accurate and acceptable for catching AF early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men and women aged 50-90 who are new or established patients in an MGH primary care or ambulatory cardiology practice * Willing to provide consent to participate in the study to access data from electronic health records (EHR) * At least 1 12-lead ECG obtained within 5 years prior to study start date for AF risk estimation * Have access to a smart phone or tablet to use with the AliveCor KardiaMobile 1L ECG device Exclusion Criteria: * History of atrial fibrillation or atrial flutter as documented in the patient's current electronic health record medical problem list or self-reported diagnosis * Implanted cardiac devices (pacemakers, implantable cardiac defibrillators, or cardiac resynchronization therapy, and implantable loop recorders) * History of allergy to adhesive
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mass General Brigham
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a checklist and heart monitor stop repeat strokes?
- Can a breathing workout and walks help dialysis patients with irregular heartbeats?
- Zapping the ear: a new way to stop Post-Surgery heart rhythm problems?
- Can a new mapping and ablation system fix recurring atrial fibrillation?
- Can shedding pounds stop atrial fibrillation in its tracks?
- Pacemaker algorithm tuned to Heart's pumping may beat standard rate response